Cargando…
Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells
Here, we developed Pluronic(®) P123/F127 (poloxamer) mixed micelles for the intravenous delivery of the anticancer drug sorafenib (SRB) or its combination with verteporfin (VP), a photosensitizer for photodynamic therapy that should complement well the cytotoxicity profile of the chemotherapeutic. S...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019320/ https://www.ncbi.nlm.nih.gov/pubmed/27660441 http://dx.doi.org/10.2147/IJN.S103344 |
_version_ | 1782453036574048256 |
---|---|
author | Pellosi, Diogo Silva Moret, Francesca Fraix, Aurore Marino, Nino Maiolino, Sara Gaio, Elisa Hioka, Noboru Reddi, Elena Sortino, Salvatore Quaglia, Fabiana |
author_facet | Pellosi, Diogo Silva Moret, Francesca Fraix, Aurore Marino, Nino Maiolino, Sara Gaio, Elisa Hioka, Noboru Reddi, Elena Sortino, Salvatore Quaglia, Fabiana |
author_sort | Pellosi, Diogo Silva |
collection | PubMed |
description | Here, we developed Pluronic(®) P123/F127 (poloxamer) mixed micelles for the intravenous delivery of the anticancer drug sorafenib (SRB) or its combination with verteporfin (VP), a photosensitizer for photodynamic therapy that should complement well the cytotoxicity profile of the chemotherapeutic. SRB loading inside the core of micelles was governed by the drug:poloxamer weight ratio, while in the case of the SRB–VP combination, a mutual interference between the two drugs occurred and only specific ratios could ensure maximum loading efficiency. Coentrapment of SRB did not alter the photophysical properties of VP, confirming that SRB did not participate in any bimolecular process with the photosensitizer. Fluorescence resonance energy-transfer measurement of micelles in serum protein-containing cell-culture medium demonstrated the excellent stability of the system in physiologically relevant conditions. These results were in line with the results of the release study showing a release rate of both drugs in the presence of proteins slower than in phosphate buffer. SRB release was sustained, while VP remained substantially entrapped in the micelle core. Cytotoxicity studies in MDA-MB231 cells revealed that at 24 hours, SRB-loaded micelles were more active than free SRB only at very low SRB concentrations, while at 24+24 hours a prolonged cytotoxic effect of SRB-loaded micelles was observed, very likely mediated by the block in the S phase of the cell cycle. The combination of SRB with VP under light exposure was less cytotoxic than both the free combination and VP-loaded micelles + SRB-loaded micelles combination. This behavior was clearly explainable in terms of micelle uptake and intracellular localization. Besides the clear advantage of delivering SRB in poloxamer micelles, our results provide a clear example that each photochemotherapeutic combination needs detailed investigations on their particular interaction, and no generalization on enhanced cytotoxic effects should be derived a priori. |
format | Online Article Text |
id | pubmed-5019320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50193202016-09-22 Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells Pellosi, Diogo Silva Moret, Francesca Fraix, Aurore Marino, Nino Maiolino, Sara Gaio, Elisa Hioka, Noboru Reddi, Elena Sortino, Salvatore Quaglia, Fabiana Int J Nanomedicine Original Research Here, we developed Pluronic(®) P123/F127 (poloxamer) mixed micelles for the intravenous delivery of the anticancer drug sorafenib (SRB) or its combination with verteporfin (VP), a photosensitizer for photodynamic therapy that should complement well the cytotoxicity profile of the chemotherapeutic. SRB loading inside the core of micelles was governed by the drug:poloxamer weight ratio, while in the case of the SRB–VP combination, a mutual interference between the two drugs occurred and only specific ratios could ensure maximum loading efficiency. Coentrapment of SRB did not alter the photophysical properties of VP, confirming that SRB did not participate in any bimolecular process with the photosensitizer. Fluorescence resonance energy-transfer measurement of micelles in serum protein-containing cell-culture medium demonstrated the excellent stability of the system in physiologically relevant conditions. These results were in line with the results of the release study showing a release rate of both drugs in the presence of proteins slower than in phosphate buffer. SRB release was sustained, while VP remained substantially entrapped in the micelle core. Cytotoxicity studies in MDA-MB231 cells revealed that at 24 hours, SRB-loaded micelles were more active than free SRB only at very low SRB concentrations, while at 24+24 hours a prolonged cytotoxic effect of SRB-loaded micelles was observed, very likely mediated by the block in the S phase of the cell cycle. The combination of SRB with VP under light exposure was less cytotoxic than both the free combination and VP-loaded micelles + SRB-loaded micelles combination. This behavior was clearly explainable in terms of micelle uptake and intracellular localization. Besides the clear advantage of delivering SRB in poloxamer micelles, our results provide a clear example that each photochemotherapeutic combination needs detailed investigations on their particular interaction, and no generalization on enhanced cytotoxic effects should be derived a priori. Dove Medical Press 2016-09-06 /pmc/articles/PMC5019320/ /pubmed/27660441 http://dx.doi.org/10.2147/IJN.S103344 Text en © 2016 Pellosi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Pellosi, Diogo Silva Moret, Francesca Fraix, Aurore Marino, Nino Maiolino, Sara Gaio, Elisa Hioka, Noboru Reddi, Elena Sortino, Salvatore Quaglia, Fabiana Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells |
title | Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells |
title_full | Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells |
title_fullStr | Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells |
title_full_unstemmed | Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells |
title_short | Pluronic(®) P123/F127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells |
title_sort | pluronic(®) p123/f127 mixed micelles delivering sorafenib and its combination with verteporfin in cancer cells |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019320/ https://www.ncbi.nlm.nih.gov/pubmed/27660441 http://dx.doi.org/10.2147/IJN.S103344 |
work_keys_str_mv | AT pellosidiogosilva pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells AT moretfrancesca pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells AT fraixaurore pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells AT marinonino pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells AT maiolinosara pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells AT gaioelisa pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells AT hiokanoboru pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells AT reddielena pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells AT sortinosalvatore pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells AT quagliafabiana pluronicp123f127mixedmicellesdeliveringsorafenibanditscombinationwithverteporfinincancercells |